drugset
drugset / Trial / NCT00768482

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

NCT00768482 ↗

Phase 3 Terminated 9 enrolled Titan Pharmaceuticals
CrossoverOpen-labelTreatment

Summary

This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).

Timeline

Start
2008-09
Primary completion
2008-12
Completion
2008-12

Outcome

Outcome not reported

Stopped: “This study was terminated for reasons not related to efficacy or safety”

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 16 mg Other
Subject Buprenorphine Other / unclassified — Other

Indications

opiate dependence